Cargando…

Frozen and freeze‐dried solvent/detergent treated plasma: Two different pharmaceutical formulations with comparable quality

BACKGROUND: OctaplasLG is a frozen solvent/detergent‐treated plasma product used for treating complex coagulation factor deficiencies or as substitution therapy in emergency situations where specific factor concentrates are not available. A new freeze‐dried (also known as lyophilized) form of Octapl...

Descripción completa

Detalles Bibliográficos
Autores principales: Heger, Andrea, Gruber, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092463/
https://www.ncbi.nlm.nih.gov/pubmed/36181447
http://dx.doi.org/10.1111/trf.17139
_version_ 1785023350493413376
author Heger, Andrea
Gruber, Gerhard
author_facet Heger, Andrea
Gruber, Gerhard
author_sort Heger, Andrea
collection PubMed
description BACKGROUND: OctaplasLG is a frozen solvent/detergent‐treated plasma product used for treating complex coagulation factor deficiencies or as substitution therapy in emergency situations where specific factor concentrates are not available. A new freeze‐dried (also known as lyophilized) form of OctaplasLG, referred as OctaplasLG Lyo (Octapharma AG, Switzerland) offers rapid reconstitution and more flexible storage conditions, improving logistics and utilization. This study compared the biochemical quality of OctaplasLG Lyo with OctaplasLG and single‐donor fresh frozen plasma units. STUDY DESIGN AND METHODS: Three batches of OctaplasLG Lyo, manufactured for production process qualification, and 12 batches of OctaplasLG were provided by Octapharma AB (Sweden). Twelve units of fresh frozen plasma were collected by the local FDA‐licensed blood provider. All plasma samples were assessed for global coagulation parameters, coagulation factors and protease inhibitors, activation markers of coagulation and fibrinolysis, and important plasma proteins. Quality control assays were conducted in accordance with European Pharmacopeia requirements. RESULTS: Frozen and freeze‐dried OctaplasLG demonstrated comparable quality profiles upon thawing or reconstitution. All coagulation factor and protease inhibitor activity parameters were in line with levels mandated by the European Pharmacopeia. Fresh frozen plasma units showed comparable coagulation factor activities, with higher protein S and plasmin inhibitor levels than the OctaplasLG products. Fresh frozen plasma parameters showed high lot‐to‐lot variations. DISCUSSION: The two pharmaceutical forms of OctaplasLG (frozen and freeze‐dried) have comparable biochemical quality. Key features of OctaplasLG Lyo are rapid reconstitution time and storage flexibility, which may improve logistics and utilization, and have particular advantages in emergency situations and pre‐hospital settings.
format Online
Article
Text
id pubmed-10092463
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-100924632023-04-13 Frozen and freeze‐dried solvent/detergent treated plasma: Two different pharmaceutical formulations with comparable quality Heger, Andrea Gruber, Gerhard Transfusion Blood Components BACKGROUND: OctaplasLG is a frozen solvent/detergent‐treated plasma product used for treating complex coagulation factor deficiencies or as substitution therapy in emergency situations where specific factor concentrates are not available. A new freeze‐dried (also known as lyophilized) form of OctaplasLG, referred as OctaplasLG Lyo (Octapharma AG, Switzerland) offers rapid reconstitution and more flexible storage conditions, improving logistics and utilization. This study compared the biochemical quality of OctaplasLG Lyo with OctaplasLG and single‐donor fresh frozen plasma units. STUDY DESIGN AND METHODS: Three batches of OctaplasLG Lyo, manufactured for production process qualification, and 12 batches of OctaplasLG were provided by Octapharma AB (Sweden). Twelve units of fresh frozen plasma were collected by the local FDA‐licensed blood provider. All plasma samples were assessed for global coagulation parameters, coagulation factors and protease inhibitors, activation markers of coagulation and fibrinolysis, and important plasma proteins. Quality control assays were conducted in accordance with European Pharmacopeia requirements. RESULTS: Frozen and freeze‐dried OctaplasLG demonstrated comparable quality profiles upon thawing or reconstitution. All coagulation factor and protease inhibitor activity parameters were in line with levels mandated by the European Pharmacopeia. Fresh frozen plasma units showed comparable coagulation factor activities, with higher protein S and plasmin inhibitor levels than the OctaplasLG products. Fresh frozen plasma parameters showed high lot‐to‐lot variations. DISCUSSION: The two pharmaceutical forms of OctaplasLG (frozen and freeze‐dried) have comparable biochemical quality. Key features of OctaplasLG Lyo are rapid reconstitution time and storage flexibility, which may improve logistics and utilization, and have particular advantages in emergency situations and pre‐hospital settings. John Wiley & Sons, Inc. 2022-10-01 2022-12 /pmc/articles/PMC10092463/ /pubmed/36181447 http://dx.doi.org/10.1111/trf.17139 Text en © 2022 The Authors. Transfusion published by Wiley Periodicals LLC on behalf of AABB. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Blood Components
Heger, Andrea
Gruber, Gerhard
Frozen and freeze‐dried solvent/detergent treated plasma: Two different pharmaceutical formulations with comparable quality
title Frozen and freeze‐dried solvent/detergent treated plasma: Two different pharmaceutical formulations with comparable quality
title_full Frozen and freeze‐dried solvent/detergent treated plasma: Two different pharmaceutical formulations with comparable quality
title_fullStr Frozen and freeze‐dried solvent/detergent treated plasma: Two different pharmaceutical formulations with comparable quality
title_full_unstemmed Frozen and freeze‐dried solvent/detergent treated plasma: Two different pharmaceutical formulations with comparable quality
title_short Frozen and freeze‐dried solvent/detergent treated plasma: Two different pharmaceutical formulations with comparable quality
title_sort frozen and freeze‐dried solvent/detergent treated plasma: two different pharmaceutical formulations with comparable quality
topic Blood Components
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092463/
https://www.ncbi.nlm.nih.gov/pubmed/36181447
http://dx.doi.org/10.1111/trf.17139
work_keys_str_mv AT hegerandrea frozenandfreezedriedsolventdetergenttreatedplasmatwodifferentpharmaceuticalformulationswithcomparablequality
AT grubergerhard frozenandfreezedriedsolventdetergenttreatedplasmatwodifferentpharmaceuticalformulationswithcomparablequality